Company: IMRX
Filing Date: 2025-09-25
Form Type: 424B5
Source: 0001104659-25-093438
Chunk: 47

Company: Immuneering Corp
Filing Date: 2025-09-25
Form: 424B5
Chunk 47
---
25, 2025and September 24, 2025.

•

The description of our common stock filed as Exhibit 4.3in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 10, 2022, and any amendment or report filed with the SEC for the purpose of updating the description.

All reports and other documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this offering, but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference in this prospectus supplement and deemed to be part of this prospectus supplement from the date of the filing of such reports and documents.

<div align='center'>S-33</div>

TABLE OF CONTENTS

You may request a free copy of any of the documents incorporated by reference in this prospectus supplement by writing or telephoning us at the following address:

#### Immuneering Corporation

#### 245 Main Street, Second Floor

#### Cambridge, MA 02142
<div align='center'>**(617) 500-8080**</div>

Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this prospectus supplement.

<div align='center'>S-34</div>

TABLE OF CONTENTS

### PROSPECTUS

### IMMUNEERING CORPORATION
<div align='center'>**$300,000,000**</div>

#### Class A Common Stock

#### Preferred Stock

#### Debt Securities

#### Warrants

#### Units
**We may offer and sell up to $300,000,000 in the aggregate of the securities identified above from time to time in one or more offerings. This prospectus provides you with a general description of the securities.

Each time we offer and sell securities, we will provide a supplement to this prospectus that contains specific information about the offering and the amounts, prices and terms of the securities. The supplement may also add, update or change information contained in this prospectus with respect to that offering. You should carefully read this prospectus and the applicable prospectus supplement before you invest in any of our securities.

We may offer and sell the securities described in this prospectus and any prospectus supplement to or through one or more underwriters, dealers and agents, or directly to purchasers, or through a combination of these methods. If